Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

BioPharma M&A: Capital Efficiency Drives Returns

Amidst lofty public markets and robust fund flows, it’s easy to forget the importance of equity capital efficiency in building new biotech companies. But like gravity, it’s a fundamental principle and rests at the heart of generating quality returns in any market. By deploying early, expensive equity dollars carefully and thoughtfully, a startup can preserve […]

Read More »

Is Sir Andrew Witty The Person To Lead A Major Pharmaceutical Company?

The success of a CEO is often predicated on the situational status of the company he or she inherits. Bill Steere took the helm at Pfizer in 1991, riding on the crest of five recently launched blockbusters: Zoloft, Norvasc, Zithromax, Diflucan, and Cardura. He then oversaw the rollout of Viagra and, if all this wasn’t […]

Read More »

U.S. class action asserts India’s Ranbaxy manipulated FDA rules

A Ranbaxy office building is pictured in the northern Indian city of Mohali May 14, 2013. Reuters/Ajay Verma Indian generic drugmaker Ranbaxy Laboratories Ltd has been sued in a district court in the United States for allegedly manipulating U.S. Food and Drug Administration rules for years to keep rival generic drugs out of the market. […]

Read More »

Ogilvy CommonHealth Worldwide’s Jill Lesiak Honored as HBA Rising Star

PARSIPPANY, NJ–(Marketwired – May 14, 2015) – Ogilvy CommonHealth Worldwide (www.ochww.com), the health behavior change experts of Ogilvy & Mather (www.ogilvy.com), and a WPP company (NASDAQ: WPPGY) (www.wpp.com), today announced Jill Lesiak, vice president, creative director at the network’s Parsippany-based agency, Ogilvy CommonHealth, was named an industry Rising Star by the Healthcare Businesswomen’s Association (HBA) […]

Read More »

Takeda Reports Top Line Results in Line With Guidance, With Underlying Growth of +2.8% EPS Affected by One-time Charges in FY2014 Back to Profitable Growth from FY2015 Onward

OSAKA, Japan, May 15, 2015 /PRNewswire/ — Operational guidance met  Growth supported by innovative new products  Regional top line performance on track  Efficiency gains above target  Exceptional items impacting bottom line  Guidance: Back to profitable growth from FY2015  180 yen dividend per share for FY2015 and strives to at least maintain the 180 yen annual dividend per […]

Read More »

Investing in Cannabis Testing Labs and Expansion of Marijuana News Focus of DigiPath, Inc., 10-Q

LAS VEGAS, May 13, 2015 /PRNewswire/ — DigiPath, Inc. (OTCBB and OTCQB: DIGP), the independent cannabis testing, media, digital pathology, and education firm, announced the filing of its quarterly report on Form 10-Q for its second fiscal quarter ended March 31, 2015, with the Securities and Exchange Commission. “DigiPath ended the quarter with $3.9 million of […]

Read More »

Puma Biotechnology Founder Auerbach Loses $250 Million On Cancer Drug Data

On Wednesday afternoon, Forbes estimated Puma Biotechnology Founder, Chairman, and Chief Executive Alan Auerbach’s net worth at $1.19 billion. Then long-awaited details on a positive clinical trial of Puma’s breast cancer drug, neratinib, were released. Puma shares, which had spiked a year ago and made Auerbach a billionaire when it was first announced the study […]

Read More »

Bolstering Cancer Strategy, German Biotech BioNTech and Eli Lilly Ink $360 Million Research Deal

Mainz, Germany-based BioNTech announced yesterday that it had signed a research collaboration agreement with Indianapolis-based Eli Lilly and Company (LLY). The deal, which starts with a $30 million signing fee, will focus on discovering novel cancer immunotherapies. In addition, Lilly is investing another $30 million equity investment in Cell & Gene Therapies GmbH, a subsidiary […]

Read More »

Baxter International Puts Down $900 Million to Beef Up Cancer Products for Spinoff

Deerfield, Ill.-based Baxter International (BAX) said Tuesday it would buy a promising leukemia treatment, Oncaspar, from Italian company Sigma-Tau Finanziaria S.p.A. for $900 million, as it bolsters its oncology pipeline in an increasingly lucrative and competitive field. Baxter estimated oncology alone could bring in $10 billion once its pipeline is established, with Oncaspar already raking […]

Read More »

GSK’s Curious Oncology Research Position – A Recipe For Failure?

In April of 2014, GSK and Novartis announced a swap of assets, with GSK acquiring the Novartis global Vaccines business (excluding influenza vaccines) and Novartis gaining the GSK Oncology business. In addition, the two companies announced the creation of a new Consumer Healthcare joint venture. At the time, GSK’s CEO Sir Andrew Witty said that: […]

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

October 2019 Focus: Top 50 Company Profiles & Financials, Outcomes Creativity Index, and more!

Subscribe

Ad Right Bottom